» Articles » PMID: 25133360

Atypical Antipsychotic Drugs and the Risk for Acute Kidney Injury and Other Adverse Outcomes in Older Adults: a Population-based Cohort Study

Overview
Journal Ann Intern Med
Specialty General Medicine
Date 2014 Aug 19
PMID 25133360
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several adverse outcomes attributed to atypical antipsychotic drugs, specifically quetiapine, risperidone, and olanzapine, are known to cause acute kidney injury (AKI). Such outcomes include hypotension, acute urinary retention, and the neuroleptic malignant syndrome or rhabdomyolysis.

Objective: To investigate the risk for AKI and other adverse outcomes associated with use of atypical antipsychotic drugs versus nonuse.

Design: Population-based cohort study.

Setting: Ontario, Canada, from 2003 to 2012.

Patients: Adults aged 65 years or older who received a new outpatient prescription for an oral atypical antipsychotic drug (n=97,777) matched 1:1 with those who did not receive such a prescription.

Measurements: The primary outcome was hospitalization with AKI (assessed by using a hospital diagnosis code and, in a subpopulation, serum creatinine levels) within 90 days of prescription for atypical antipsychotic drugs.

Results: Atypical antipsychotic drug use versus nonuse was associated with a higher risk for hospitalization with AKI (relative risk [RR], 1.73 [95% CI, 1.55 to 1.92]). This association was consistent when AKI was assessed in a subpopulation for which information on serum creatinine levels was available (5.46% vs. 3.34%; RR, 1.70 [CI, 1.22 to 2.38]; absolute risk increase, 2.12% [CI, 0.80% to 3.43%]). Drug use was also associated with hypotension (RR, 1.91 [CI, 1.60 to 2.28]), acute urinary retention (RR, 1.98 [CI, 1.63 to 2.40]), and all-cause mortality (RR, 2.39 [CI, 2.28 to 2.50]).

Limitation: Only older adults were included in the study.

Conclusion: Atypical antipsychotic drug use is associated with an increased risk for AKI and other adverse outcomes that may explain the observed association with AKI. The findings support current safety concerns about the use of these drugs in older adults.

Primary Funding Source: Academic Medical Organization of Southwestern Ontario.

Citing Articles

A Pharmacovigilance Study on Psychotropic Agent-Induced Urinary Retention Using the Japanese Adverse Drug Event Report Database.

Uekusa S, Mogi K, Ota Y, Hanai Y, Kitagawa K, Yoshio T Drugs Real World Outcomes. 2024; 11(4):691-700.

PMID: 39537981 PMC: 11589045. DOI: 10.1007/s40801-024-00465-8.


Higher dose antiviral therapy for herpes infections is associated with a risk of serious adverse events in older adults with chronic kidney disease.

Olar P, Garg A, Weir M, Ahmadi F, McArthur E, Lam N Pharmacol Res Perspect. 2024; 12(6):e70028.

PMID: 39428714 PMC: 11491552. DOI: 10.1002/prp2.70028.


Risk of renal impairment in atypical antipsychotics: a systematic review and meta-analysis.

Ong L, Chee N, Loh A Eur J Clin Pharmacol. 2024; 80(10):1435-1444.

PMID: 38916726 DOI: 10.1007/s00228-024-03714-5.


Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.

Mok P, Carr M, Guthrie B, Morales D, Sheikh A, Elliott R BMJ. 2024; 385:e076268.

PMID: 38631737 PMC: 11022137. DOI: 10.1136/bmj-2023-076268.


High-Throughput Computing to Automate Population-Based Studies to Detect the 30-Day Risk of Adverse Outcomes After New Outpatient Medication Use in Older Adults with Chronic Kidney Disease: A Clinical Research Protocol.

Abdullah S, Rostamzadeh N, Muanda F, McArthur E, Weir M, Sontrop J Can J Kidney Health Dis. 2024; 11:20543581231221891.

PMID: 38186562 PMC: 10771740. DOI: 10.1177/20543581231221891.